Business Update
Crucell awarded contracts of over $230 million for Quinvaxem and Hepavax-Gene vaccines
Published in Vaccine Weekly, January 3rd, 2007
The contracts cover the next three years until 2009, with the awarded amount growing over those three years.
Following the WHO prequalification in September 2006 the combination vaccine was made available to supranational purchasing organizations. Supranational organizations are major customers for combination vaccines, which are used in large vaccination programs in developing countries.
Quinvaxem, a fully-liquid...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2007-01-03)
More Articles from Vaccine Weekly
- Hepatitis C Virus
Inovio Biomedical partner Tripep applies for phase I study of hepatitis C DNA vaccine - DNA Vaccines
Scientists at Beth Israel Deaconess Medical Center, Division of Viral Pathogenesis release new data on DNA vaccines - Vaccine Efficacy
Researchers from Mahidol University detail findings in vaccine efficacy - Atherosclerosis Vaccine
Human clinical trials will begin at the end of next year on first vaccine against atherosclerosis - Avian Influenza
HepaLife's PBS-1 cells for avian influenza vaccine achieve research objective - Business Update
Immunomedics reports on 2006 annual meeting of shareholders - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
